Professional societies are implementing measures to limit transmission of SARS-CoV-2 at conferences, as oncology groups reconvene in-person annual meetings for the first time since early 2020. The American Society of Clinical Oncology will require proof of vaccination, encourage indoor masking, and provide masks onsite—regardless of mandates and regulations—at its upcoming annual meeting June 3-7 in... […]
The COVID-19 pandemic disrupted cancer screening and treatment and exacerbated health disparities, but also created unexpected opportunities in cancer research and care, a recent report from the American Association for Cancer Research states.
As we head into the third year of the global COVID-19 pandemic, everyone would just like it to be over.
As omicron infections and hospitalizations continue to peak in the U.S., a high-stakes battle over the national public health response is being fought in the rafters of political Washington.
After having treated over 200,000 COVID cases over two years—more than any health system in the U.S.—Northwell Health once again finds itself in the center of the storm as cases of the omicron variant escalate in New York State.
In early 2020, telehealth was a hot new trend in patient care, but with utilization sporadic and episodic at best, providers were generally skeptical as to whether this virtual technique of delivering care was a viable option for advanced clinical services, especially in oncology.
In surveys, as many as 15% of Americans say that they will not get a COVID-19 vaccine under any circumstances, and another 17% are in the “wait-and-see” category, holding out to observe how others fare.If these numbers are correct, the U.S. has almost no wiggle room as it strives to reach herd immunity to COVID-19.
In a matter of months, cancer researchers have gone from grappling with a surge of COVID-19 with limited clinical data to playing a critical role in the development of successful mRNA vaccines against the disease.
Faced with a pandemic that kills thousands of Americans each day, FDA leadership had to get therapeutics and vaccines for SARS-CoV-2 onto the market with unprecedented speed without sacrificing standards.
When Uğur Şahin and his wife Özlem Türeci founded their company, BioNTech, in 2008, they set out to explore novel modalities for treating cancer—including messenger ribonucleic acid, a well-understood single-stranded molecule featured in most Biology 101 textbooks.
